Treatment Patterns Among Patients with Rheumatoid Arthritis in Puerto Rico
ConclusionsThese findings demonstrate that despite the availability of several b/tsDMARDs, patients with RA in Puerto Rico still experience substantial treatment disruption, with almost two-thirds of patients discontinuing their index therapy within 2 years. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 24, 2022 Category: Rheumatology Source Type: research
Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still ’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
ConclusionThe analyses presented support the similarity of clinical outcomes following treatment with canakinumab in patients with sJIA and AOSD. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 19, 2022 Category: Rheumatology Source Type: research
Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)
ConclusionsThis Spanish cohort of patients treated with baricitinib had a long-standing and refractory disease. Nevertheless, high persistence and improvements in disease activity and pain were found at 6 and 12 months after treatment initiation, independently of the composite disease activity measure used, reinforcing the effectiveness of baricitinib in routine clinical practice. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 18, 2022 Category: Rheumatology Source Type: research
Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results from a Real-World Survey in the USA and Europe
ConclusionsCRP was more commonly used for the diagnosis and monitoring of PsA in Europe compared to the USA and was more commonly ordered by rheumatologists than dermatologists. In the absence of a better serum biomarker of inflammation, more data are needed to understand how CRP testing should be used in the diagnosis and management PsA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 15, 2022 Category: Rheumatology Source Type: research
Primary Antiphospholipid Syndrome with and Without Acute Myocardial Infarction/Angina: A Cross-Sectional Study
ConclusionspAPS patients and AMI-A have distinct clinical and laboratory spectra from those without AMI-A. It is characterized by dyslipidemia and hypertension, hyper lipoprotein(a), and a lower IgM anticardiolipin frequency. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 9, 2022 Category: Rheumatology Source Type: research
Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
ConclusionsThis study supports leflunomide as co-therapy to pegloticase in uncontrolled gout patients. Heterogeneity and high comorbidity burden in uncontrolled gout patients makes having a variety of immunomodulators options important. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 8, 2022 Category: Rheumatology Source Type: research
Total Hip Replacement in Patients with Rheumatoid Arthritis: Trends in Incidence and Complication Rates Over 35 Years
ConclusionsOver the last 30 years in RA patients, THR IR and mechanical complication rates decreased significantly, but the medical complication of infection has not changed significantly. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 8, 2022 Category: Rheumatology Source Type: research
Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials
ConclusionsThese results suggest baricitinib-treated patients with RA achieving MCID improvement in PROs at weeks 4 and 12 maintained those improvements over time and that substantial PRO responses were achieved quickly. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - January 6, 2022 Category: Rheumatology Source Type: research
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
ConclusionsUpadacitinib 15 mg and adalimumab had similar safety profiles with the exception of HZ and OIs, consistent with what was observed in rheumatoid arthritis. Rates of malignancies, MACEs, VTEs, and deaths were comparable among patients receiving upadacitinib and adalimumab. No new safety risks emerged with longer-te rm exposure to upadacitinib.Trial Registration NumbersSELECT-PsA 1: NCT03104400; SELECT-PsA 2: NCT03104374. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 30, 2021 Category: Rheumatology Source Type: research
Comparison of Clinical Manifestations in Rheumatoid Arthritis vs. Spondyloarthritis: A Systematic Literature Review
ConclusionsTypical SpA-related clinical symptoms and signs were observed in patients with RA, suggesting that misclassification could occur. Availability of advanced imaging modalities may allow for more prompt and comprehensive evaluation of peripheral manifestations in SpA and RA, reducing misclassification and delayed diagnosis. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 28, 2021 Category: Rheumatology Source Type: research
Australian Consensus Statements for the Assessment and Management of Non-radiographic Axial Spondyloarthritis
ConclusionsWe provide 22 evidence-based consensus statements to provide practical guidance in the assessment and management of nr-axSpA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 28, 2021 Category: Rheumatology Source Type: research
Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication
ConclusionsIn a predominantly female sample of bDMARD-treated patients with axSpA/AS and high disease activity, the majority expressed treatment satisfaction. However, most experienced wear-off between doses and relied on supplemental medications, including opioids, to manage symptoms. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 27, 2021 Category: Rheumatology Source Type: research
The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
ConclusionsCumulative prednisone exposure is associated with increased BMI in GCA patients. In those with newly diagnosed disease, effective disease control regardless of the treatment used also contributes to BMI increase. Modest weight gain may be an indicator of adequate treatment response. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 25, 2021 Category: Rheumatology Source Type: research
Ultrasound Features of Adhesive Capsulitis
ConclusionsWe believe a sufficiently experienced US specialist can confirm a clinical diagnosis of AC by carrying out a comparative study of APs, evaluating the thickness of the CHL and SGHL, and detecting reduced sliding of the infraspinatus tendon. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 23, 2021 Category: Rheumatology Source Type: research
Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA
ConclusionsPatients who initiated abatacept or rituximab and were ACPA+ had a greater clinical response at 6-month follow-up post index compared to patients who were ACPA– treated with the same biologic. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - December 23, 2021 Category: Rheumatology Source Type: research
